Infectious disease specialist Dr. Rontgene Solante, a Vaccine Expert Panel (VEP) member, stated that Sinovac’s clinical trial data will be reviewed for use in kids and adolescents. The age range for the trial is likely 3 to 17 years old. This is on the heels of China issuing an EUA (emergency use authorization) for the vaccine on youngsters.
The national Technical Advisory Group’s Dr. Edsel Salvana, acknowledged the approval from China as good news, since it could lead to more approved vaccines for young people. However, the EUA being amended in terms of age range is not instant. The manufacturer, Sinovac Biotech, still has to file an application for the Sinovac trial within the Philippines.
On June 6, a million Sinovac doses was received by the Philippines. At the moment, the EUA of Sinovac in the Philippines recommends use for those 18 years old and above. The same applies for its emergency use listing under the World Health Organization.
The US-manufactured vaccine Pfizer has already undergone evaluation by the VEP. While reports have come out that VEP director general Eric Domingo said the result was favorable, no formal announcement about EUA adjustments for Pfizer has been made yet. Initially, Pfizer received an EUA for people that were at least 16 years old.
Last month, the US Centers for Disease Control and Prevention (CDC) recommended vaccination against COVID-19 for people at least 12 years old.
In the Philippines, at present, the minimum is still 18 years old. Vaccination has begun starting with frontline workers, such as medical professionals.